Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis

Samir S Shoughy,1 Mahmoud O Jaroudi,1 Khalid F Tabbara1–3 1The Eye Center and The Eye Foundation for Research in Ophthalmology, 2Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3Wilmer Ophthalmological Institute of the Johns Hopkins University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shoughy SS, Jaroudi MO, Tabbara KF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Topical Solution Tacrolimus Vernal keratoconjunctivities Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a0a5c83737254a3ba644ccb8c5504e3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0a5c83737254a3ba644ccb8c5504e3f
record_format	dspace
spelling	oai:doaj.org-article:a0a5c83737254a3ba644ccb8c5504e3f2021-12-02T06:37:07ZEfficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis1177-5483https://doaj.org/article/a0a5c83737254a3ba644ccb8c5504e3f2016-04-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-low-dose-topical-tacrolimus-in-vernal-keratocon-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Samir S Shoughy,1 Mahmoud O Jaroudi,1 Khalid F Tabbara1–3 1The Eye Center and The Eye Foundation for Research in Ophthalmology, 2Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3Wilmer Ophthalmological Institute of the Johns Hopkins University School of Medicine, Baltimore, MD, USA Objective: The objective of this study was to evaluate the efficacy and safety of topical low-dose tacrolimus (0.01%) solution in patients with vernal keratoconjunctivitis (VKC). Patients and methods: A total of 62 consecutive patients with VKC refractory to conventional treatment were included retrospectively. Tacrolimus 0.01% ophthalmic solution was administered to patients twice daily after discontinuation of all previous topical medications. The duration of treatment ranged from 1 month to 29 months. The clinical symptoms of itching, redness, foreign body sensation, and discharge and the clinical signs of conjunctival hyperemia, conjunctival papillary hypertrophy, limbal infiltration, Trantas dots, and superficial punctate keratopathy were graded as 0 (normal), 1+ (mild), 2+ (moderate), or 3+ (severe). Assessment was carried out before initiation of therapy and on the last visit after treatment. Results: There were 62 patients with VKC comprising 49 male and 13 female patients. The median age was 12 years (range: 5–47 years). The mean visual acuity improved from 20/30 to 20/25 following treatment. There was statistically significant improvement in symptoms of itching (P<0.001), redness (P<0.001), foreign body sensation (P<0.001), and discharge (P<0.001). Statistically significant improvement was also observed in clinical signs of conjunctival hyperemia (P<0.001), limbal infiltration (P<0.001), Trantas dots (P<0.001), superficial punctate keratopathy (P<0.001), and conjunctival papillary hypertrophy (P<0.001). The solution form of tacrolimus was well tolerated. None of the patients developed elevation of intraocular pressure, cataract, or infectious keratitis. Conclusion: Low-dose topical tacrolimus 0.01% solution is effective and safe in the management of patients with refractory VKC. Keywords: topical, solution, tacrolimus, vernal keratoconjunctivitisShoughy SSJaroudi MOTabbara KFDove Medical PressarticleTopicalSolutionTacrolimusVernal keratoconjunctivitiesOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 643-647 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Topical Solution Tacrolimus Vernal keratoconjunctivities Ophthalmology RE1-994
spellingShingle	Topical Solution Tacrolimus Vernal keratoconjunctivities Ophthalmology RE1-994 Shoughy SS Jaroudi MO Tabbara KF Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
description	Samir S Shoughy,1 Mahmoud O Jaroudi,1 Khalid F Tabbara1–3 1The Eye Center and The Eye Foundation for Research in Ophthalmology, 2Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 3Wilmer Ophthalmological Institute of the Johns Hopkins University School of Medicine, Baltimore, MD, USA Objective: The objective of this study was to evaluate the efficacy and safety of topical low-dose tacrolimus (0.01%) solution in patients with vernal keratoconjunctivitis (VKC). Patients and methods: A total of 62 consecutive patients with VKC refractory to conventional treatment were included retrospectively. Tacrolimus 0.01% ophthalmic solution was administered to patients twice daily after discontinuation of all previous topical medications. The duration of treatment ranged from 1 month to 29 months. The clinical symptoms of itching, redness, foreign body sensation, and discharge and the clinical signs of conjunctival hyperemia, conjunctival papillary hypertrophy, limbal infiltration, Trantas dots, and superficial punctate keratopathy were graded as 0 (normal), 1+ (mild), 2+ (moderate), or 3+ (severe). Assessment was carried out before initiation of therapy and on the last visit after treatment. Results: There were 62 patients with VKC comprising 49 male and 13 female patients. The median age was 12 years (range: 5–47 years). The mean visual acuity improved from 20/30 to 20/25 following treatment. There was statistically significant improvement in symptoms of itching (P<0.001), redness (P<0.001), foreign body sensation (P<0.001), and discharge (P<0.001). Statistically significant improvement was also observed in clinical signs of conjunctival hyperemia (P<0.001), limbal infiltration (P<0.001), Trantas dots (P<0.001), superficial punctate keratopathy (P<0.001), and conjunctival papillary hypertrophy (P<0.001). The solution form of tacrolimus was well tolerated. None of the patients developed elevation of intraocular pressure, cataract, or infectious keratitis. Conclusion: Low-dose topical tacrolimus 0.01% solution is effective and safe in the management of patients with refractory VKC. Keywords: topical, solution, tacrolimus, vernal keratoconjunctivitis
format	article
author	Shoughy SS Jaroudi MO Tabbara KF
author_facet	Shoughy SS Jaroudi MO Tabbara KF
author_sort	Shoughy SS
title	Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
title_short	Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
title_full	Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
title_fullStr	Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
title_full_unstemmed	Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
title_sort	efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/a0a5c83737254a3ba644ccb8c5504e3f
work_keys_str_mv	AT shoughyss efficacyandsafetyoflowdosetopicaltacrolimusinvernalkeratoconjunctivitis AT jaroudimo efficacyandsafetyoflowdosetopicaltacrolimusinvernalkeratoconjunctivitis AT tabbarakf efficacyandsafetyoflowdosetopicaltacrolimusinvernalkeratoconjunctivitis
_version_	1718399829929885696

Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis

Ejemplares similares